Merck to Participate in the Goldman Sachs 44th Annual Global Healthcar...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: April 25, 2024

Elder Care Alliance Communities Among Best Again by U.S. News & World Report • Marmon Foodservice Technologies Emissions Near-term Targets Validated by the Science Based Targets Initiative • UrbanGeekz Inks Groundbreaking Content Syndication Deal with Black-Owned Ridesharing App Moovn • AHF Withdraws Bid to Purchase Skid Row Housing Trust Buildings • Spellers™ Method Launches TV Series For Autism Awareness • Wells Fargo Expands Down Payment Grant Program to Help Bridge Homeownership Gap • Vagaro Survey Highlights Neurodiversity in the Salon & Spa Industry • REI Path Ahead Ventures celebrates 16 emerging companies bringing new innovations and perspectives to the outdoor industry • August Health Unveils Inaugural Members of New Advisory Board • Pure Spout Highlights Importance of Clean Water Through Lead Exposure Prevention in Grade Schools • Ramp Metals Inc. (TSXV: RAMP) Opens the Market • BABE BY BUCKED UP MAKES ITS OFFICIAL DEBUT IN MAJOR RETAILERS NATIONWIDE • Alterra Mountain Company Closes Acquisition of Mike Wiegele Helicopter Skiing in British Columbia Final • Introducing Home Planet Fund: A radically different approach to the climate crisis • Historically Black Colleges and Universities in Georgia and Florida Join Forces with SouthStar Energy Services in Sustainability • OpenGate Capital Completes Sale of SMAC • Raptive and BOMESI Partner to Unlock Large-Scale Investment in Diverse-Owned Media • Attorneys File Sexual Assault Lawsuit Against Fort Worth Massage Envy • American College of Lifestyle Medicine and National Medical Association announce partnership to address chronic disease health d • ComEd Joins Bronzeville Community to Unveil New Public EV Chargers

Merck to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

RAHWAY, N.J. , June 06 /Businesswire/ - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Caroline Litchfield, executive vice president and chief financial officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Monday, June 12, 2023, at 4:00 p.m. PDT / 7:00 p.m. EDT.

Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink.

About Merck

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2022 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).